Thyroid Hormones membrane receptor, Integrin αvβ3, as a potential prognostic marker of chemotherapy response in breast cancer

DÍAZ ALBUJA JA; STERLE HA; CAYROL F; PAULAZO A; CAMPOS HAEDO MATEO; DEBERNARDI M; ROSEMBLIT, CINTHIA; CREMASCHI GRACIELA; DIAZ FLAQUE MARIA CELESTE

Congreso; ENDO 2022; 2022

Despite the development of novel therapies, breast cancer (BC) tumors are treated with conventional therapy sooner or later. Due to tumor heterogeneity, it is necessary to define new biomarkers to identify groups with different molecular characteristic and on this basis improve the treatment decision. The impact of thyroid status in BC growth has previously been studied. In particular, alterations of thyroid function during chemotherapy for BC treatment have been found and it has been demonstrated that T3 induces chemosensitization of BC cells. However, the relationship between thyroid hormones (THs) membrane receptor, integrin αvβ3, and BC response to chemotherapy remains unclear. The aim of this study is to evaluate the relationship between THs and integrin αvβ3 expression as prognostic value in BC patients.The mRNA expression of ITGB3 in the TCGA-PanCancer Atlas BC dataset (1084 patients) was associated with worse overall survival. Moreover, ITGB3 mRNA expression was significantly correlated with genes encoding multidrug resistance protein transporters MDR1 and BCRP such as ABCB1 and ABCG2, (Pearson, R score >0.3 and p